

## Targeting Fibrosis in Pancreatic Ductal Adenocarcinoma: Emerging Role of Endothelial-to-Mesenchymal Transition

Pratiek N Matkar<sup>1</sup>, Hao H Chen<sup>1</sup>, Antoinette Bugyei-Twum<sup>1</sup>, Howard Leong-Poi<sup>1</sup> and Krishna Kumar Singh<sup>2,3\*</sup>

<sup>1</sup>Division of Cardiology, Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Ontario M5B 1W8, Canada

<sup>2</sup>Division of Cardiac, Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Ontario M5B 1W8, Canada

<sup>3</sup>Division of Vascular Surgery, Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Ontario M5B 1W8, Canada

### Opinion

Despite advances in our understanding of tumour biology and rapid strides in cancer therapies, malignant tumours remain a leading cause of morbidity and mortality [1-3]. Among these tumours, pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of mortality worldwide, with the lowest five-year survival rate [4-6]. Therefore, development of novel therapeutic strategies remains the urgent need of the hour. Poorly vascularized tumours like PDAC have remained largely untreatable despite the substantial innovations in anti-angiogenesis therapies [7,8]. At the morphological level, PDAC is characterized by an intense fibrotic reaction called tumour desmoplasia, primarily composed of the cancer-associated fibroblasts (CAFs) along with other stromal cells [9-12]. Recent findings have highlighted the crucial role of CAFs in numerous oncogenic events through alteration of the tumour microenvironment by releasing oncogenic as well as angiogenic factors [13-15]. Highly fibrotic PDAC tumours are often resistant to chemotherapy and radiation therapy due to high interstitial pressure and tumour microenvironment. This raised the question, "Could evolution of anti-fibrosis therapies treat PDAC?"

The origin of fibroblasts in pathological conditions is complex and multifactorial. Traditionally, adult fibroblasts are derived directly from embryonic mesenchymal cells and increase in number due to proliferation of resident fibroblasts [13,16]. In the setting of diseases like cancer, epithelial-to-mesenchymal transition (EMT) has been studied extensively as an important mechanism of invasion and metastasis. Recent studies have suggested that during fibrosis, endothelial cells (ECs) demonstrate an unusual cellular plasticity that contributes towards fibroblast accumulation through endothelial-to-mesenchymal transition (EndMT) in addition to the proliferation of resident fibroblast [13-17]. During EndMT, resident ECs delaminate from an organized cell layer and invade the underlying tissue. This resultant mesenchymal phenotype is characterized by reduced expression of endothelial markers and increased expression of mesenchymal markers, as well as the loss of cell-cell junctions and the acquisition of invasive and migratory phenotypes [18]. EndMT-derived cells function as fibroblasts in damaged tissue and have an important role in tissue remodeling and the development of fibrosis. A plethora of studies have investigated the role of EndMT in physiological processes like development of primitive heart [19] and process of wound healing [20].

However, maladaptive EndMT has been implicated in a variety of fibrotic pathologies including cancer [21,22]. Zeisberg et al. validated through lineage tracing studies that up to 40% of CAFs were derived via EndMT [22]. Furthermore, other reports have suggested that endothelium could also be the source of vascular support cells, such as pericytes and/or smooth muscle cells, thereby indicating that EndMT may be an essential mechanism in recruiting mural cells during angiogenesis [23]. Additionally, these mural cells are an integral component of mature blood vessels, and hence EndMT may also contribute in stabilizing the neovasculature for maturation.

Mechanistically, several studies have demonstrated the role of TGF $\beta$  signaling in regulating EndMT [24]. Also, TGF $\beta$  signaling is aberrantly active in PDAC; therefore suggesting that fibrosis in PDAC may be derived from TGF $\beta$ -mediated EndMT. *In vitro* studies have also implicated Notch pathways in modulating EndMT [25]. However, mechanistic work focusing on *in vivo* EndMT in the context of pathological conditions like PDAC remains unclear and warrants additional enquiry. Other signaling pathways like VEGF, BMP, Wnt/ $\beta$ -catenin have been extensively investigated in physiological EndMT [26] but their involvement in EndMT is yet to be determined conclusively. Additionally, the roles of downstream transcription effectors like Snail, Slug and Twist in EndMT within PDAC remain undecided. Paracrine action of endothelial cells through Snail and CTGF on fibroblast proliferation has been reported [27]. Recently, through a systematic line of inquiry, we have shown for the first time the role of TGF $\beta$ -mediated EndMT in PDAC using *in vitro* and *in vivo* approaches (Unpublished data). We are further investigating the therapeutic potential of limiting EndMT in a clinically relevant rodent model of human PDAC.

Taken altogether, the fibroblasts play a vital role in several cancer initiating and progression events and form an integral component of tumour stroma. Although, the fibroblasts could be recruited through multiple sources, EndMT is emerging as a major source in tumour fibrosis. Given the crucial role of EndMT, we believe that targeting EndMT in PDAC could inhibit tumour growth and metastasis, possibly through compromised angiogenesis and CAF recruitment. Future treatment strategies could target the TGF $\beta$  signaling due to its diverse role not only in EndMT, but also in other oncogenic events. Nevertheless, further studies are necessary to identify and validate the detailed molecular mechanisms of EndMT as well as their possible paracrine role in PDAC, and investigate their therapeutic potential. Finally, to maximize the effect of targeting EndMT, it is imperative to identify tumours harboring aberrant EndMT and activated fibroblast populations. Combination of chemotherapeutics, small molecule inhibitors of aforementioned pathways and radiation therapy may lead to a more synergistic therapeutic benefit and needs to be considered.

**\*Corresponding author:** Krishna Kumar Singh, 5E21, Division of Cardiac and Vascular Surgery, St. Michael's Hospital, 209 Victoria Street, Toronto, Ontario, M5B 1T8, Canada, Tel: 416-864-6060 (extn-77626); Fax: 416- 864-5497; E-mail: [singhk@smh.ca](mailto:singhk@smh.ca)

**Received:** November 30, 2015; **Accepted:** December 03, 2015; **Published:** December 05, 2015

**Citation:** Matkar PN, Chen HH, Bugyei-Twum A, Leong-Poi H, Singh KK (2015) Targeting Fibrosis in Pancreatic Ductal Adenocarcinoma: Emerging Role of Endothelial-to-Mesenchymal Transition. J Cell Sci Ther 6: 231. doi:10.4172/2157-7013.1000231

**Copyright:** © 2015 Matkar PN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Acknowledgments

This work was supported by a grant from the Krembil Foundation. PNM is a recipient of the Peterborough K.M. Hunter Charitable Foundation Graduate Award, Faculty of Medicine, University of Toronto. HL-P is supported by the Brazilian Ball Chair in Cardiovascular Research from St. Michael's Hospital, University of Toronto.

## References

1. Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. *Cancer Epidemiology. Biomarkers Prev* 19: 1893-1907.
2. Phillips KA, Milne RL, West DW, Goodwin PJ, Giles GG, Chang ET, et al. (2009) Prediagnosis reproductive factors and all-cause mortality for women with breast cancer in the breast cancer family registry. *Cancer Epidemiol Biomarkers Prev* 18: 1792-1797.
3. Autier P, Boniol M, La Vecchia C, Vatten L, Gavin A, et al. (2010) Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. *BMJ* 341:c3620.
4. Chang MC, Wong JM, Chang YT (2014) Screening and early detection of pancreatic cancer in high risk population. *World J Gastroenterol* 20: 2358-2364.
5. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. *CA Cancer J Clin* 60: 277-300.
6. Yadav D, Lowenfels AB (2013) The epidemiology of pancreatitis and pancreatic cancer. *Gastroenterology* 144: 1252-1261.
7. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). *J Clin Oncol* 28: 3617-3622.
8. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, et al. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. *Science* 324: 1457-1461.
9. Hernandez-Munoz I, Skoudy A, Real FX, Navarro P (2008) Pancreatic ductal adenocarcinoma: cellular origin, signaling pathways and stroma contribution. *Pancreatology* 8: 462-469.
10. Solcia E, Rindi G, Paolotti D, Luinetti O, Klersy C, et al. (1998) Natural history, clinicopathologic classification and prognosis of gastric ECL cell tumors. *Yale J Biol Med* 71: 285-290.
11. Hruban RH, Goggins M, Parsons J, Kern SE (2000) Progression model for pancreatic cancer. *Clin Cancer Res* 6: 2969-2972.
12. Chu GC, Kimmelman AC, Hezel AF, DePinho RA (2007) Stromal biology of pancreatic cancer. *J Cell Biochem* 101: 887-907.
13. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. *Nat Rev Cancer* 6: 392-401.
14. Tlsty TD, Hein PW (2001) Know thy neighbor: stromal cells can contribute oncogenic signals. *Curr Opin Genet Dev* 11: 54-59.
15. Brierie B, Moses HL (2006) TGF-beta and cancer. *Cytokine Growth Factor Rev* 17: 29-40.
16. Moore-Morris T, Guimaraes-Camboa N, Banerjee I, Zambon AC, Kisseleva T, et al. (2014) Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. *J Clin Invest* 124: 2921-2934.
17. Singh KK, Lovren F, Pan Y, Quan A, Ramadan A, et al. (2015) The essential autophagy gene ATG7 modulates organ fibrosis via regulation of endothelial-to-mesenchymal transition. *J Biol Chem* 290: 2547-2559.
18. Goumans MJ, van Zonneveld AJ, ten Dijke P (2008) Transforming growth factor beta-induced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis? *Trends Cardiovasc Med* 18: 293-298.
19. Markwald RR, Fitzharris TP, Smith WN (1975) Structural analysis of endocardial cytodifferentiation. *Dev Biol* 42: 160-80.
20. Lee JG, Kay EP (2006) FGF-2-mediated signal transduction during endothelial mesenchymal transformation in corneal endothelial cells. *Exp Eye Res* 83: 1309-1316.
21. Potenta S, Zeisberg E, Kalluri R (2008) The role of endothelial-to-mesenchymal transition in cancer progression. *Br J Cancer* 99: 1375-1379.
22. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R (2007) Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. *Cancer Res* 67: 10123-10128.
23. Armulik A, Abramsson A, Betsholtz C (2005) Endothelial/pericyte interactions. *Circ Res* 97: 512-523.
24. Medici D, Potenta S, Kalluri R (2011) Transforming growth factor-beta2 promotes Snail-mediated endothelial-mesenchymal transition through convergence of Smad-dependent and Smad-independent signalling. *Biochem J* 437: 515-520.
25. Nosedá M, McLean G, Niessen K, Chang L, Pollet I, Montpetit R, et al. (2004) Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformation. *Circ Res* 94: 910-917.
26. Armstrong EJ, Bischoff J (2004) Heart valve development: endothelial cell signaling and differentiation. *Circ Res* 95: 459-470.
27. Lee SW, Won JY, Kim WJ, Lee J, Kim KH, Youn SW, et al. (2013) Snail as a potential target molecule in cardiac fibrosis: paracrine action of endothelial cells on fibroblasts through snail and CTGF axis. *Mol Ther* 21: 1767-1777.